en · de · es · pt
epitalon-notes.peptides3081.com › Wiki › Research Claims And Evidence Status — Questions and Answers

Research Claims And Evidence Status — Questions and Answers

By Editorial Desk · published 2025-09-14 · last reviewed 2025-10-06 · Wiki

reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-10-06. Where a claim depends on a specific study, the study is described rather than over-claimed.

Research Claims and Evidence Status

The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.

Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.

Identity and Research Background

Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.

The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.

Epitalon at a glance

PropertyValueNotes
Regulatory statusNot an approved drugMarketed in most countries as a research chemical
Main literature languageRussian and EnglishEarly reports concentrated in Russian journals
Typical stated purity≥95% by HPLCSupplier declaration, seldom independently verified
Principal studied endpointTelomerase activity in vitroMeasured in cultured human cells
Reported administration routesSubcutaneous, intranasalDescribed in exploratory use reports

Stability Handling and Quality Control

Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.

Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.

Related pages on this site

Epitalon Background and Discovery

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.

The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.

Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.

Supporting material

Among these, the recently described (2023) fungus Tremella parietinae is found exclusively on X. parietina, where it induces the formation of convex, orange to yellow galls within the hymenium of its apothecia. This fungus is known from several European countries—including Austria, Spain, and Sweden—and likely has a broader distribution wherever its host occurs. Another lichenicolous fungus, Tremella occultixanthoriae, parasitizes X. parietina but develops on the lower surface of the thallus and produces four-celled basidia. Both fungi belong to a broader complex of Tremella species that specialize in infecting Teloschistaceae lichens, often with strict host specificity. Some common saprotrophic fungi not typically associated with lichens have also been found colonizing X. parietina. These include Epicoccum nigrum, appearing as dark purple-brown hemispherical heaps on the surface of apothecial discs, and Periconia digitata, which forms distinctive stalked spherical heads resembling tiny pins on the apothecia and thallus. The environmental conditions that trigger such extensive fungal colonization remain unclear, although factors like prolonged snow cover, high rainfall, or other environmental stressors may initially weaken the lichen, making it susceptible to fungal invasion. Another lichenicolous fungus is Arthonia parietinaria, which was long misidentified as Arthonia molendoi or A. epiphyscia. This species forms mat black, dull ascomata that are arranged in large groups of up to 20–30 (sometimes 50) on the thallus surface of X.

CEND-1, also known as iRGD, is a cyclic peptide that homes to tumors via binding to integrin alpha V receptors. It also binds and activates neuropilin-1, leading to a temporary opening of the tumor and an enhanced delivery of anti-cancer agents into the tumor tissue. It is currently being tested in clinical trials in solid tumor patients.

Via Roma crosses one of the main squares of the city: the pedestrianised Piazza San Carlo, built by Carlo di Castellamonte in the 17th century. In the middle of the square stands the equestrian monument to Emmanuel Philibert, also known as Caval ëd Brons in the local dialect ('Bronze Horse'); the monument depicts the Duke sheathing his sword after the Battle of St. Quentin. Piazza San Carlo arcades host the most ancient cafés of the city, such as Caffé Torino and Caffé San Carlo.

Sources: en.wikipedia.org

Notes from published material

Allan L. Goldstein is emeritus professor in the Department of Biochemistry and Molecular Medicine at the George Washington University School of Medicine. He chaired the department from 1978 until March 2009 and was awarded emeritus status in 2013. He is an authority on the thymus gland and the workings of the immune system, and co-discoverer (with Abraham White) of the thymosins, a family of hormone-like peptides isolated from the thymus gland.

This is a list of investigational sexual dysfunction drugs, or drugs that are currently under development for clinical use for the treatment of sexual dysfunction but are not yet approved. Sexual function disorders include anorgasmia, atrophic vaginitis (vaginal atrophy), decreased libido, dyspareunia (painful sexual intercourse), erectile dysfunction, female sexual dysfunction (female sexual arousal disorder (FSAD)/hypoactive sexual desire disorder (HSSD)), male sexual dysfunction, premature ejaculation, vulvodynia (vulva pain), paraphilias, and hypersexuality, among others. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]". The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications. This list was last comprehensively updated in January 2026. It is likely to become outdated with time.

== Programs == Since 1999, CLASP has worked in over 50 countries on six continents. Some of CLASP's past program locations include Argentina, Brazil, Egypt, Fiji, Ghana, Poland, South Africa, Tunisia, and Uruguay. CLASP currently has programs in China, Brazil, Europe, Southeast Asia, East Africa, India, and the United States, collaborating with policymakers, regulators, and their stakeholders to facilitate the development and implementation of energy efficiency S&L. Additionally, CLASP has two global programs—Global Research and the SEAD Initiative—which create original technical research, facilitate information exchange among countries, and disseminate S&L best practices internationally. In 2021, 15 countries signed SEAD's Product Efficiency Call to Action, which aims to double the efficiency of lighting, residential cooling, residential refrigeration, and industrial electric motor systems globally by 2030.

The potential of epitaxial graphene on SiC for metrology has been shown since 2010, displaying quantum Hall resistance quantization accuracy of three parts per billion in monolayer epitaxial graphene. Over the years precisions of parts-per-trillion in the Hall resistance quantization and giant quantum Hall plateaus have been demonstrated. Developments in the encapsulation and doping of epitaxial graphene have led to the commercialization of epitaxial graphene quantum resistance standards. Novel uses for graphene continue to be researched and explored. One such use is in combination with water-based epoxy resins to produce anticorrosive coatings. The van der Waals nature of graphene and other two-dimensional (2D) materials also permits van der Waals heterostructures and integrated circuits based on Van der Waals integration of 2D materials. Graphene is utilized in detecting gasses and chemicals in environmental monitoring, developing highly sensitive biosensors for medical diagnostics, and creating flexible, wearable sensors for health monitoring. Graphene's transparency also enhances optical sensors, making them more effective in imaging and spectroscopy.

Sources: en.wikipedia.org

Further detail

Having shown that enzymes could function outside a living cell, the next step was to determine their biochemical nature. Many early workers noted that enzymatic activity was associated with proteins, but several scientists (such as Nobel laureate Richard Willstätter) argued that proteins were merely carriers for the true enzymes and that proteins per se were incapable of catalysis. However, in 1926, James B. Sumner showed that the enzyme urease was a pure protein and crystallized it; Sumner did likewise for the enzyme catalase in 1937. The conclusion that pure proteins can be enzymes was definitively proved by Northrop and Stanley, who worked on the digestive enzymes pepsin (1930), trypsin, and chymotrypsin. These three scientists were awarded the 1946 Nobel Prize in Chemistry. This discovery, that enzymes could be crystallized, meant that scientists eventually could solve their structures by x-ray crystallography. This was first done for lysozyme, an enzyme found in tears, saliva, and egg whites that digests the coating of some bacteria; the structure was solved by a group led by David Chilton Phillips and published in 1965. This high-resolution structure of lysozyme marked the beginning of the field of structural biology and the effort to understand how enzymes work at an atomic level of detail.

== Preparation == To make a gelatine dessert, gelatine is dissolved in hot liquid with the desired flavours and other additives. These latter ingredients usually include sugar, fruit juice, or sugar substitutes; they may be added and varied during preparation, or pre-mixed with the gelatine in a commercial product which mainly requires the addition of hot water. In addition to sweeteners, the prepared commercial blends generally contain flavouring agents and other additives, such as adipic acid, fumaric acid, sodium citrate, and artificial flavourings and food colours. Because the collagen is processed extensively, the final product is not categorised as a meat or animal product by the United States federal government.

She argued that women, unlike men, did not have locker room experiences in school where they compared each other's genitals, which is one reason so many women wonder if their genitals are normal. Scholar Catherine Blackledge stated that having a vagina meant she would typically be treated less well than her vagina-less counterparts and subject to inequalities (such as job inequality), which she categorized as being treated like a second-class citizen.

Sources: en.wikipedia.org

Frequently asked questions

Has epitalon been studied in people?

Small studies with human participants have been reported, chiefly in Russian-language journals, but they are limited in size and design. No large randomised controlled trial with published results is available.

What is the strongest evidence for its activity?

The most reproducible biochemical observation comes from cultured cells, where the peptide was reported to raise telomerase activity. Whether this translates into measurable health effects in animals or humans is not established.

Why is epitalon sold online?

It is offered as a research chemical for laboratory use, which places it outside the approval pathways applied to medicines. Buyers should expect documentation to differ between suppliers.

What is epitalon?

Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.

Network